Analysis of Tricyclic Antidepressant Drugs In Plasma for Clinical Research

Significance of the Topic

Accurate quantification of tricyclic antidepressants in plasma is essential for pharmacokinetic studies, therapeutic monitoring and drug development research. This method offers rapid throughput, minimal sample volume and robust performance, addressing key needs in clinical pharmacology and bioanalysis.

Objectives and Study Overview

This work describes a validation of an LC-MS/MS protocol for simultaneous analysis of 15 tricyclic antidepressants in human plasma. The primary objectives were to achieve fast quantification, high sensitivity and reproducibility suitable for clinical research.

Methodology and Instrumentation

• Sample Preparation: Protein precipitation using 50 µL plasma with 150 µL acetonitrile containing stable-labeled internal standards, vortex mixing, centrifugation, and dilution of supernatant.
• Chromatographic Conditions: Waters ACQUITY UPLC I-Class FTN system with XSelect Premier HSS T3 C18 column (2.1 x 100 mm, 2.5 µm) using a methanol/water gradient with 5 mM ammonium formate, 4-minute run time.
• Detection: Waters Xevo TQ-S micro triple quadrupole in positive ESI mode with multiple reaction monitoring for each analyte and its internal standard.

Main Results and Discussion

• Linearity: Calibration curves for all analytes showed r2 > 0.995 over target ranges.
• Sensitivity: Lower limit of measuring interval met precision ≤20% CV and bias ≤15% at lowest calibrator.
• Precision and Accuracy: Repeatability and total CV ≤8.0% across low, mid and high QC levels; mean method bias <14.75% against EQA samples.
• Matrix Effects and Carryover: Normalized matrix factors ranged 0.88–1.07, stable-labeled standards compensated ion suppression; no significant carryover observed.
• Interference Testing: Endogenous compounds and lipids evaluated, with minor interference (<17%) for select analytes at low levels.

Benefits and Practical Applications of the Method

This protocol allows rapid, high-throughput analysis of multiple tricyclic antidepressants using minimal sample volume. Its robustness and simplicity make it suitable for pharmacokinetic studies, therapeutic drug monitoring and large-scale clinical trials.

Future Trends and Potential Applications

Advancements in high-resolution mass spectrometry and microflow chromatography may further reduce analysis time and sample volume. Integration with automated sample preparation and expanding panels to novel psychoactive compounds will enhance throughput and scope.

Conclusion

The validated UHPLC-MS/MS method provides accurate, precise and efficient quantification of 15 tricyclic antidepressants in plasma. Its fast turnaround, low sample requirement and strong performance metrics support its adoption in clinical research environments.

References

1. Waters Corporation application data;
2. External Quality Assurance scheme data (LGC, UK).